Advertisement

Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px
Document › Details

Bayer AG. (2/4/22). "Press Release: Bayer Will Discontinue Phase II Development Candidate eliapixant [only for specialized press]". Berlin.

Organisations Organisation Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
  Group Evotec (Group)
  Organisation 2 Bayer Pharma division
  Group Bayer (Group)
Products Product eliapixant (BAY 1817080)
  Product 2 phase 2 study
     


   
Record changed: 2022-02-07

Advertisement

Picture [iito] No Tracking 650x100px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px




» top